Search
Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors8-azaguanine
go.drugbank.com/drugs/DB01667Experimental8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesRutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalA flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Synonyms: Vitamin PCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby
Categories: Thrombopoietin Receptor Agonist, P-glycoprotein substratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigational[A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates